Quick Answer
China SXT Pharmaceuticals, Inc. reported Total Revenue of $1.93 million for fiscal year 2024.
China SXT Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | $1.93M -2.2% |
$1.97M -24.2% |
$2.60M -45.5% |
$4.78M -7.5% |
$5.16M -26.4% |
| Net Income | -$3.30M -6.6% |
-$3.10M +47.8% |
-$5.93M -3.5% |
-$5.74M -108.7% |
-$2.75M +73.3% |
-$10.29M -768.4% |
| Diluted EPS | -$2.32 +91.9% |
-$28.58 +83.9% |
-$177.84 -28.9% |
-$137.92 -3511.4% |
-$3.82 | — |
| Total Assets | $21.66M -6.3% |
$23.13M -21.7% |
$29.55M -11.9% |
$33.55M -2.9% |
$34.55M +59.2% |
$21.70M +24.2% |
| Cash and Equivalents | $18.10M +49.9% |
$12.07M -30.5% |
$17.37M | — | $13.36M +83.3% |
$7.29M -21.6% |
| Long-Term Debt | $96.3K -17.8% |
$117.1K -0.6% |
$117.9K | — | $6.3K -82.8% |
$36.5K -12.5% |
| Stockholders Equity | $15.44M +10.8% |
$13.93M -5.2% |
$14.69M -8.7% |
$16.08M +0.8% |
$15.96M +69.8% |
$9.40M -15.4% |
| Operating Income | -$2.68M -6.6% |
-$2.52M +55.1% |
-$5.61M -8.1% |
-$5.19M -136.2% |
-$2.20M -63.8% |
-$1.34M -175.8% |
| Gross Profit | $367.4K -33.7% |
$554.0K +30.0% |
$426.3K -65.9% |
$1.25M -55.9% |
$2.84M +5.0% |
$2.70M -41.4% |
| Shares Outstanding | 13.76M +0.0% |
13.76M +2909.3% |
457,365 -77.5% |
2.03M +161.7% |
776,255 -91.0% |
8.67M -61.8% |
- China SXT Pharmaceuticals, Inc. reported Total Revenue of $1.93 million for fiscal year 2024.
- China SXT Pharmaceuticals, Inc. showed a decrease of -2.2% in Total Revenue compared to the prior fiscal year.
- China SXT Pharmaceuticals, Inc. reported Net Income of -$3.30 million for fiscal year 2025.
- China SXT Pharmaceuticals, Inc. showed a decrease of -6.6% in Net Income compared to the prior fiscal year.
- China SXT Pharmaceuticals, Inc. reported Diluted EPS of $2.32 per share (loss) for fiscal year 2025.
- China SXT Pharmaceuticals, Inc. showed an increase of +91.9% in Diluted EPS compared to the prior fiscal year.
- China SXT Pharmaceuticals, Inc. reported Total Assets of $21.66 million for fiscal year 2025.
- China SXT Pharmaceuticals, Inc. showed a decrease of -6.3% in Total Assets compared to the prior fiscal year.
- China SXT Pharmaceuticals, Inc. reported Cash and Equivalents of $18.10 million for fiscal year 2025.
- China SXT Pharmaceuticals, Inc. showed an increase of +49.9% in Cash and Equivalents compared to the prior fiscal year.
- China SXT Pharmaceuticals, Inc. reported Long-Term Debt of $96.3 thousand for fiscal year 2025.
- China SXT Pharmaceuticals, Inc. showed a decrease of -17.8% in Long-Term Debt compared to the prior fiscal year.
- China SXT Pharmaceuticals, Inc. reported Stockholders Equity of $15.44 million for fiscal year 2025.
- China SXT Pharmaceuticals, Inc. showed an increase of +10.8% in Stockholders Equity compared to the prior fiscal year.
- China SXT Pharmaceuticals, Inc. reported Operating Income of -$2.68 million for fiscal year 2025.
- China SXT Pharmaceuticals, Inc. showed a decrease of -6.6% in Operating Income compared to the prior fiscal year.
- China SXT Pharmaceuticals, Inc. reported Gross Profit of $367.4 thousand for fiscal year 2025.
- China SXT Pharmaceuticals, Inc. showed a decrease of -33.7% in Gross Profit compared to the prior fiscal year.
- China SXT Pharmaceuticals, Inc. reported Shares Outstanding of 13.76 million shares for fiscal year 2025.
- China SXT Pharmaceuticals, Inc. showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: